Abstract
The increased risk of onset or recurrence of bipolar disorders during the perinatal period raises the crucial question of management of mood stabilizers. Women and their partners have to be informed and helped to be able to give an informed consent for the choice that they make. For clinicians, the prescription of mood stabilizers, as that of any psychotropic drug during pregnancy, is challenging, and they have to be able to weigh the risk of a maternal relapse vs. the risk of antenatal exposure to the drug, that is, should treatment be interrupted or modified against the teratogenic or fetotoxic risk of antenatal exposure to the drug.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168:1179â85.
Van der Lugt NM, Van de Maat JS, Van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88:375â8.
Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry. 2005;186:453â4.
Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.
Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(Suppl 4):42â55.
Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170:1240â7.
Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83:16â29.
Zhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016;202:26â31.
Sutter-Dallay AL, Bales M, Pambrun E, Glangeaud-Freudenthal NM, Wisner KL, Verdoux H. Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry. 2015;76:967â73.
Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162:2162â70.
Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des. 2006;12:1531â41.
Schou M, Goldfield MD, Weinstein MR, Villieneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. BMJ. 1973;2:135â6.
Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry. 1975;132:529â31.
Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am J Med Genet A. 2005;132A(4):441â4.
Nora JJ, Nora AH, Toews WH. Lithium, Ebsteinâs anomaly, and other congenital heart defects. Lancet. 1974;2(7880):594â5.
Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245â54.
Zalzstein E, Koren G, Einarson T, Freedom RM. A case-control study on the association between first trimester exposure to lithium and Ebsteinâs anomaly. Am J Cardiol. 1990;65:817â8.
Boyle B, Garne E, Loane M, Addor MC, Arriola L, Cavero-Carbonell C, Gatt M, Lelong N, Lynch C, Nelen V, Neville AJ, OâMahony M, Pierini A, Rissmann A, Tucker D, Zymak-Zakutnia N, Dolk H. The changing epidemiology of Ebsteinâs anomaly and its relationship with maternal mental health conditions: a European registry-based study. Cardiol Young. 2017;27:677â85.
Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339(8792):530â3.
Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11:425â37.
Diav-Citrin O, Shechtman S, Tahover E. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171:785â94.
Mcknight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721â8.
Bergink V, Kushner SA. Lithium during pregnancy. Am J Psychiatry. 2014;171:712â5.
Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol. 2001;39:381â92.
Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon WA Jr, Konradi C. Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci. 2006;26:6031â9.
Forsberg L, Adler M, Römer Ek I, Ljungdahl M, Naver L, Gustafsson LL, Berglund G, Chotigasation A, Hammar U, Böhm B, Wide K. Maternal mood disorders and lithium exposure in utero were not associated with poor cognitive development during childhood. Acta Paediatr. 2018;107:1379. https://doi.org/10.1111/apa.14152.
Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: a systematic review. Aust N Z J Psychiatry. 2017;51:1087â97.
Wesseloo R, Wierdsma AI, van Kamp IL, Munk-Olsen T, Hoogandijk WJG, Kushner SA, Bergink V. Lithium dosing strategies during pregnancy and the postpartum period. Br J Psychiatry. 2017a;211:31â6.
NICE. NICE guidelines. Antenatal and postnatal mental health: clinical management and service guidance [CG192]. London: NICE; 2014.
Viguera AC, Nonacs R, Cohen LS Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179â84.
Viguera AC, Whitfield T, Baldessarini RJ Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817â24.
Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6:2â13.
Bank AM, Stowe ZN, Newport DJ, Ritchie RJ, Pennell PB. Placental passage of antiepileptic drugs at delivery and neonatal outcomes. Epilepsia. 2017;58:e82â6.
Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry. 2010;44:99â108.
Campbell E, Kennedy F, Russell A. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2014;85:1029â34.
Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579â88.
Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, GarcĂa-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G, Meador KJ, Shallcross R, Clayton-Smith J, Liverpool and Manchester Neurodevelopment Group. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84:382â90.
Van der Pol MC, Hadders-Algra M, Huisjes HJ, Touwen BC. Antiepileptic medication in pregnancy: late effects on the childrenâs central nervous system development. Am J Obstet Gynecol. 1991;164:121â8.
Gedzelman E, Kimford J, Meador MD. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Safe. 2012;3:71â87.
HernĂĄndez-DĂaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB, North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692â9.
Eriksson K, Viinikainen K, Mönkkönen A, AikiĂ€ M, Nieminen P, Heinonen S, KĂ€lviĂ€inen R. Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005;65:189â200.
Casassus B. France bans sodium valproate use in case of pregnancy. Lancet. 2017;390(10091):217.
Arkilo D, Hanna J, Dickens D. Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. Eur J Paediatr Neurol. 2015;19:37â40.
Kong L, Zhou T, Wang B, Gao Z, Wang C. The risks associated with the use of lamotrigine during pregnancy. Int J Psychiatry Clin Pract. 2018;22:2â5.
Wesseloo R, Liu X, Clark CT, Kushner SA, Munk-Olsen T, Bergink V. Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. J Affect Disord. 2017b;218:394â7.
Alsaad AM, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reprod Toxicol. 2015;20:45â50.
Hernandez-Diaz S, Huybrechts KF, Desai RJ Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology. 2018;90:e342â51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sutter-Dallay, AL., Gressier, F. (2019). Mood Stabilizers in Pregnancy. In: Uguz, F., Orsolini, L. (eds) Perinatal Psychopharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-92919-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-92919-4_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92918-7
Online ISBN: 978-3-319-92919-4
eBook Packages: MedicineMedicine (R0)